Drug Type Monoclonal antibody |
Synonyms TATX 26, TATX26 |
Target |
Action inhibitors |
Mechanism TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 12 Oct 2022 | |
Solid tumor | Discovery | United States | 01 Mar 2025 | |
Solid tumor | Discovery | United States | 01 Mar 2025 | |
Solid tumor | Discovery | Belgium | 01 Mar 2025 |